414 related articles for article (PubMed ID: 30638898)
1. [Use of blinatumomab in children acute lymphoblastic leukemia in the Grand Ouest interregion: A chance for all].
Camuset M; Grain A; Lorton F; Minckes O; Jourdain A; Millot F; Pellier I; Gandemer V; Battisti FR
Bull Cancer; 2019 Mar; 106(3):206-215. PubMed ID: 30638898
[TBL] [Abstract][Full Text] [Related]
2. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
[TBL] [Abstract][Full Text] [Related]
3. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
4. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
6. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
[TBL] [Abstract][Full Text] [Related]
7. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
9. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
10. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
11. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
12. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
15. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
[TBL] [Abstract][Full Text] [Related]
18. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
